No retraction, correction or concern found when last checked on Oct 21, 2026.

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

Howard L Kaufman, Carl E Ruby, Tasha Hughes and 1 more

Journal for ImmunoTherapy of Cancer · 2014 · Review

doi:10.1186/2051-1426-2-11

Abstract

In 2012, it was estimated that 9180 people in the United States would die from melanoma and that more than 76,000 new cases would be diagnosed. Surgical resection is effective for early-stage melanoma, but outcomes are poor for patients with advanced disease. Expression of tumor-associated antigens by melanoma cells makes the disease a promising candidate for immunotherapy. The hematopoietic cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) has a variety of effects on the immune system including activation of T cells and maturation of dendritic cells, as well as an ability to promote humoral and cell-mediated responses. Given its immunobiology, there has been interest in strategies incorporating GM-CSF in the treatment of melanoma. Preclinical studies with GM-CSF have suggested that it has antitumor activity against melanoma and can enhance the activity of anti-melanoma vaccines. Numerous clinical studies have evaluated recombinant GM-CSF as a monotherapy, as adjuvant with or without cancer vaccines, or in combination with chemotherapy. Although there have been suggestions of clinical benefit in some studies, results have been inconsistent. More recently, novel approaches incorporating GM-CSF in the treatment of melanoma have been evaluated. These have included oncolytic immunotherapy with the GM-CSF-expressing engineered herpes simplex virus talimogene laherparepvec and administration of GM-CSF in combination with ipilimumab, both of which have improved patient outcomes in phase 3 studies. This review describes the diverse body of preclinical and clinical evidence regarding use of GM-CSF in the treatment of melanoma.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 21, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

1In 2012, it was estimated that 9180 people in the United States would die from melanoma and more than 76,000 new cases would be diagnosed. The primary treatment for melanoma, excision of the malignancy, is highly effective in early-stage disease but is not a meaningful option for metastatic disease except in patients with solitary metastases or limited-volume disease. For patients with advanced disease, cytotoxic chemotherapy has a limited role and curative potential in <1% of patients. For BRAF-mutant patients, treatment with vemurafenib, dabrafenib, and/or tremetinib have high rates of objective response, but median duration of response is typically ~6–8 months, after which rapid disease progression is common. However, some patients with melanoma respond to immunotherapy with durable responses, and thus immunotherapy shows substantial promise for further improving durable control of advanced melanoma.

2Expression of tumor-associated antigens by melanoma cells makes the disease a promising candidate for immunotherapy. The potential for immunotherapy in melanoma has been demonstrated by improved outcomes among patients with stage III melanoma receiving interferon-α2b and patients with metastatic melanoma receiving the anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody ipilimumab alone or in combination with a gp100 peptide vaccine or dacarbazine, as well as by durable complete responses with high-dose interleukin-2 and high response rates after adoptive T cell transfer therapies.

3The hematopoietic cytokine granulocyte–macrophage colony-stimulating factor (GM-CSF) has been investigated as a monotherapy, and as a component of combination therapies for melanoma. Preclinical evidence has suggested that GM-CSF may have antitumor effects, but results from clinical trials evaluating GM-CSF present a complex picture. This review evaluates evidence regarding use of GM-CSF in melanoma and potential future strategies in this setting.

Immunobiology of GM-CSF

4GM-CSF was identified as a factor responsible for expansion and activation of granulocytes and macrophages, but has since been found to have many direct and indirect effects on multiple cell types, including cell proliferation, maturation, and survival (Figure 1A). GM-CSF plays a critical role in development and maturation of dendritic cells (DCs) and proliferation and activation of T cells, linking the innate and acquired immune response. In mice, increased numbers of eosinophils, monocytes, macrophages, and lymphocytes were observed in the draining lymph node in response to treatment with irradiated melanoma cells expressing GM-CSF, resulting in a sustained antitumor response. GM-CSF has also been shown to favor expansion of DC1 populations and to increase DC-mediated responses to tumor cells (Figure 1B). In vitro studies using human myeloid leukemia cells suggest that, in addition to promoting antigen presentation, GM-CSF directs these cells toward a DC phenotype. The role of GM-CSF in neutrophil proliferation and survival led to its use in amelioration of neutropenia following induction chemotherapy in elderly patients with acute myeloid leukemia.

Studies evaluating GM-CSF in preclinical models of melanoma

5The immune adjuvant properties of GM-CSF led to numerous preclinical studies assessing the ability of GM-CSF to inhibit tumor growth and/or mediate tumor regression. In a seminal study, a panel of recombinant retroviral vectors expressing various cytokines, co-stimulatory molecules, or adhesion molecules were used to infect murine B16 melanoma cells. Infected cells were then irradiated and injected subcutaneously into immune-competent hosts, followed by a subsequent challenge with wild-type B16 cells. The GM-CSF–secreting tumor vaccines conveyed 90% protection, whereas vaccines expressing interleukin-2 and interferon-γ failed to mediate antitumor protection. Additionally, analysis of the vaccination site revealed an influx of dividing monocytes and granulocytes, with a coincident increase in lymphocytes in tumor-draining lymph nodes, suggesting direct augmentation of antigen presentation and T-cell priming against the tumor.

6Exogenously administered GM-CSF has been shown to augment antitumor immunity Mice immunized with an HIV envelope peptide vaccine plus GM-CSF exhibited increased cytotoxic T lymphocyte (CTL) activity compared with vaccine alone or vaccine with interleukin-2. Studies using a tumor-associated antigen vaccine (neu), in combination with GM-CSF, produced increased neu-specific antibodies alongside an enhanced CTL response. However, tumor protection was ultimately dependent on a cell-mediated response since depletion of CD8+ T cells abrogated tumor regression.

7Genetically modified vaccines can generate protective anti-melanoma immune responses in animal models. B16 tumor lines expressing bioactive levels of murine GM-CSF have been generated and assessed. Levels of GM-CSF at the site of GM-CSF–expressing tumor transplantation remain elevated for days, whereas GM-CSF dissipated rapidly after injection of irradiated tumor with recombinant GM-CSF. The pharmacokinetic longevity associated with the vaccine correlated with both increased DC infiltration and tumor protection against wild-type tumors.

8Oncolytic immunotherapy with modified herpes simplex viruses (HSV) and vaccinia viruses expressing GM-CSF have also shown promise. These vectors have elicited tumor responses in mice when injected directly into tumor lesions. In a murine melanoma model, a temperature-sensitive strain of HSV encoding murine GM-CSF significantly reduced Harding-Passey melanoma tumor growth and improved survival of tumor-bearing mice. Similarly, preclinical studies demonstrated a potent lytic effect against lesions injected with the GM-CSF–expressing oncolytic HSV talimogene laherparepvec (T-VEC; formerly OncovexGM-CSF). Notably, when virus expressing GM-CSF was employed, regression of uninjected, distant lesions was enhanced compared with a regression observed with a control virus not expressing GM-CSF.

9The combination of GM-CSF–secreting tumor vaccines with other immunotherapies is another potentially promising approach. Antibodies that block the co-inhibitory T-cell molecules CTLA-4 and PD-1 plus GM-CSF have boosted immune responses against melanomas. Additionally, activation of co-stimulatory molecules (CD80, CD86, CD137), exogenous cytokine administration (interleukin-2, interferon-γ), and blockade of tumor angiogenesis can inhibit melanoma progression when combined with GM-CSF–expressing vaccines. These preclinical studies strongly suggest that the combination of GM-CSF–based tumor vaccines with immunomodulatory agents has potential for clinical use.

Clinical trials evaluating exogenously administered GM-CSF in patients with melanoma

10Given the evidence of antitumor activity in preclinical models of melanoma, there has been interest in using GM-CSF to improve outcomes in the clinical setting. Numerous studies have evaluated use of recombinant GM-CSF in completely resected stage III/IV melanoma patients. Data from these studies, however, have been inconsistent.

GM-CSF as an adjuvant therapy

11GM-CSF has been evaluated as an adjuvant, systemic monotherapy following regional lymphadenectomy, to prevent or to delay recurrence in high-risk stage III patients (Table 1). In a phase 2 study, there were statistically significant improvements in survival among patients with stage III/IV disease (P = 0.04 and P < 0.001, respectively) receiving GM-CSF (125 μg/m2 daily for 14 consecutive days in 28-day cycles up to 1 year) compared with historical controls. A subsequent single-arm study using the same dosing regimen evaluated treatment with GM-CSF over 3 years and reported a 5-year survival rate of 60%, with 5-year disease-free survival (DFS) of 67% and 40% for patients with stage III and IV disease, respectively. The effect of GM-CSF on DC has been proposed as a mechanism for supporting antitumor immunity; consistent with this hypothesis, treatment with recombinant GM-CSF has increased mature DCs in melanoma patients. A randomized study of recombinant GM-CSF (125 μg/m2 daily for 14 consecutive days in 28-day cycles) versus placebo in patients with completely resected stage IIIB/IIIC/IV or mucosal melanoma, there was a trend toward improvement in DFS although it did not reach statistical significance (11.5 vs 9.2 months; HR, 0.88; P = 0.14), and no improvement in overall survival (OS; 69.6 vs 62.4 months; HR, 0.96; P = 0.78). However, an improvement in DFS (HR, 0.74; P = 0.04) and a trend toward improved OS (HR, 0.72; P = 0.07) was observed in stage IV patients (n = 258).

GM-CSF as intratumoral monotherapy

12Several small studies have evaluated GM-CSF administered as a monotherapy by direct injection into metastatic lesions (Table 2). Clinical responses in two of these studies were modest, with only one partial response (PR) and no complete response (CR) reported. In contrast, a study using perilesional injection of GM-CSF (400 μg/d over 5 days) to treat metastatic melanoma described reduced lesion size in 6/7 patients and a reduction in cutaneous metastases in 5/7 patients. Three patients were still alive at 5-years follow-up; a fourth died tumor-free at age 93. In these studies, there was evidence of increases in DC and T-cell counts and infiltration at injected sites, and in some cases at uninjected sites, suggesting an immunologic effect of GM-CSF injection. Other studies using novel methods (such as aerosolization and immunoembolization) to delivering GM-CSF to melanoma metastases at sites that are not readily injectable have met with mixed results (Table 2).

GM-CSF in combination with chemotherapy

13A number of early-phase clinical studies have evaluated GM-CSF in conjunction with chemotherapy (Table 3). These studies were typically small with a single-arm design and used a variety of different drug regimens and dosing schedules; thus, as a whole, they are difficult to interpret. Clinical efficacy in studies varied widely, with response rates ranging from no response to >40%. It is worth noting that several of the studies reporting high overall response rates also reported significant increases in T-cell, DC, macrophage, or natural killer–cell populations following treatment. One study evaluating a chemotherapy regimen of dacarbazine, interferon-α2b, interleukin-2, and tamoxifen with three doses of GM-CSF reported a dose–response effect with increasing exposure to GM-CSF via administration over a greater number of days (P = 0.016).

GM-CSF as an adjuvant with cancer vaccines

14Given the significant body of evidence from preclinical studies, GM-CSF has been evaluated as an adjuvant to cancer vaccines in a number of clinical studies. Several approaches to administering GM-CSF as an adjuvant have been employed, including coadministration with the vaccine, injection at the vaccination site systemic administration, and administration of a plasmid/viral vector encoding GM-CSF. The dose of GM-CSF administered as an adjuvant is typically less than the recommended overall weekly dose of 250 μg/m2/day for 21 days for use in myeloid reconstitution after autologous bone marrow transplantation.

15In contrast to data from murine studies, the adjuvant effect of GM-CSF in human trials is inconsistent. In a study that evaluated coadministration of GM-CSF with multipeptide (including gp100 and tyrosinase peptides) melanoma vaccines incorporating GM-CSF and incomplete Freund’s adjuvant (IFA) in patients with advanced melanoma, there was a high T-cell response rate and a correlation between T-cell reactivity to the melanoma peptides and clinical outcome. GM-CSF combined with IFA as an adjuvant for a vaccine containing 12 melanoma peptides resulted in a similar immunologic response in patients with resected stage III/IIIB/IV melanoma. Similarly, systemic administration of GM-CSF following a peptide vaccination augmented T-cell response in three patients with advanced melanoma. However, in a study that evaluated intradermal vaccination with tyrosinase peptides followed by intradermal GM-CSF, detectable T-cell responses were observed in only 4/15 (27%) evaluable patients.

16Although results from these studies have suggested that administration of adjuvant GM-CSF might improve immune responses, none included control groups. Recently, clinical trials including controls have evaluated effects of GM-CSF administered locally at the vaccination site (Table 4). In a phase 1 study comparing different adjuvant strategies, vaccination with tyrosinase peptide plus GM-CSF or keyhole limpet hemocyanin (KLH) did not induce greater immune responses compared with vaccination with peptide alone, although combination with GM-CSF plus KLH had a moderate adjuvant effect. Two recent randomized prospective trials suggested that addition of GM-CSF to melanoma vaccines did not improve cellular immune responses and, indeed, may have had negative effects. Notably, both studies combined GM-CSF with another adjuvant (IFA or BCG) which may have influenced the immune response. The inconsistent effect of GM-CSF on immune responses to vaccines may be due in part to competing effects inducing dendritic cell maturation on one hand, and inducing myeloid suppressor cells on the other. A recent phase 2, randomized controlled trial (E1696) evaluated treatment of advanced melanoma with multipeptide vaccine alone or with subcutaneous interferon-α, GM-CSF, or interferon-α plus GM-CSF. Consistent with results of studies evaluating administration of GM-CSF at the vaccine site, no significant improvement in T-cell or clinical response was observed with interferon-α and/or GM-CSF administration with vaccination.

17Results from clinical studies evaluating GM-CSF as an adjuvant to melanoma vaccines suggest the biologic effects of GM-CSF are complex and can be influenced by numerous factors. GM-CSF administered with a heat shock protein vaccine has been implicated in the induction of myeloid-derived suppressor cells (MDSC) in melanoma patients. On the other hand, daily subcutaneous administration of GM-CSF (125 μg/m2 for 14 days in 28-day cycles) increased circulating mature DC but did not increase MDSC in melanoma patients. It has been suggested that negative immunologic effects of GM-CSF may be associated primarily with high doses of GM-CSF (doses of 225 μg/d or higher in melanoma patients). In a trial of a multipeptide melanoma vaccine, immune responses were lower with GMCSF plus IFA than with IFA alone (the dose used in that trial was arguably less than 20 μg/day). Thus, even low doses of GM-CSF administered with a multipeptide vaccine may have negative immunologic effects. Additional studies are also needed to determine if GM-CSF alters the function of vaccine-induced T cells and whether inclusion of GM-CSF with the vaccine may affect clinical outcome.

GM-CSF–expressing oncolytic immunotherapy

18Preclinical studies have indicated an important role for GM-CSF in the tumor microenvironment and have suggested that increased expression of GM-CSF can inhibit tumor growth. However, administration of exogenous recombinant GM-CSF appears insufficient to mediate clinically meaningful improvements in outcomes in most instances. Consequently, there has been significant interest in novel treatment approaches incorporating GM-CSF.

19Among the most extensively evaluated agents is the attenuated, oncolytic, herpes simplex virus, type 1 (HSV-1)–encoding human GM-CSF talimogene laherparepvec (T-VEC; formerly OncovexGM-CSF). The vector was generated from the HSV JS1 strain and was attenuated by functional deletion of the ICP34.5 and ICP47 viral genes, which renders the virus nonpathogenic in normal eukaryotic cells, promotes selective replication in tumor cells, and enhances immunogenicity T-VEC has also been engineered to encode human GM-CSF, which further enhances the antitumor immune response. T-VEC is proposed to have a dual mechanism of action resulting in local tumor destruction by introduction of an oncolytic virus into tumor cells and induction of a systemic antitumor immune response.

20In a phase 1 study, patients with subcutaneous or cutaneous metastases from breast, gastrointestinal, head and neck, or melanoma malignancies were treated with T-VEC. Clinically stable disease was noted in 3/26 patients administered intralesional T-VEC, with no patients having CR or PR during the study period. However, follow-up biopsies in 14/19 patients showed necrosis, infiltration of T cells, and the presence of replicating virus. Notably, there was evidence of expression of GM-CSF in injected lesions. In a subsequent phase 2 study among 50 patients with unresectable stage IIIC/IV melanoma administered intralesional T-VEC, the overall response rate was 26% (8 CR, 5 PR). Two additional patients were rendered disease-free by surgical resection following treatment. One-year survival was 58% for all patients and 40% among patients with stage IVM1c disease. Immunologic analysis of a subset of patients enrolled in the phase 2 study confirmed the presence of both local and distant antitumor immune responses following T-VEC administration. Biopsies performed on 11 patients after their sixth intratumoral injection were compared to nonstudy patients with metastatic melanoma. In general, postvaccination tumors demonstrated extensive lymphocyte infiltration. Evaluation of both injected and noninjected lesions in T-VEC–treated patients revealed a significant increase in MART-1–specific T-cell response in both tumor and distant disease sites compared with unvaccinated controls. Regulatory CD4+FoxP3+ and suppressor CD8+FoxP3+ T cells and myeloid-derived suppressor cells were evaluated in injected tumor biopsies and found to be decreased when compared to unvaccinated control patients. When primary injected lesions were compared to distant noninjected lesions, the same general phenotypic pattern of effector T-cell and Treg infiltrates was seen; a greater number of CD4+FoxP3+ and CD8+FoxP3+ cells were present at the nontarget site than at the target sites. A randomized, phase 3 study, OPTiM, comparing intralesional T-VEC to subcutaneous GM-CSF demonstrated an improvement in durable response rate (16% vs 2%, respectively) and a trend toward improved OS at interim analysis (HR, 0.79 [95% CI, 0.61–1.02]) favoring the T-VEC arm. The most frequently occurring adverse events were fatigue, chills, and pyrexia.

Systemic combination immunotherapy

21GM-CSF has also been combined with ipilimumab, an anti-CTLA-4 monoclonal antibody. In a multicenter, phase 2 study, patients with metastatic melanoma were randomized to treatment with ipilimumab plus GM-CSF (250 μg/d subcutaneously for 14 days in 21-day cycles) or ipilimumab alone. Patients receiving combination therapy experienced a significant improvement in 1-year OS. Although there were no significant differences in overall toxicity between the treatment arms, patients receiving combination therapy had a lower rate of serious adverse events.

22Several other approaches utilizing GM-CSF are being developed. These include an oncolytic vaccinia virus encoding GM-CSF, autologous dendritic cells and allogeneic whole tumor cells encoding GM-CSF, adjuvant GM-CSF following vaccination with peptide or RNA encoding melanoma peptides and autologous dendritic cell or whole tumor cell vaccines, and GM-CSF DNA vaccines.

Conclusions

23GM-CSF has been studied extensively in murine models and in human clinical trials, alone and as adjuvant therapy for melanoma. There is evidence from numerous studies that GM-CSF can induce antitumor immunity when administered by a variety of different routes. Although there was initial enthusiasm for recombinant GM-CSF based on uncontrolled clinical trials in stage III/IV melanoma, therapeutic benefit has not been confirmed in larger, prospective, randomized trials. The adjuvant or combination use of GM-CSF has been more promising although results have been inconsistent and may depend on the potency of the immunotherapy regimen, GM-CSF dose, route and schedule of administration, and stage of disease. There is emerging evidence that GM-CSF may be a regulatory cytokine with the ability to promote both effector and regulatory/suppressor T cell populations. Thus, strategies that block suppressor T cell and myeloid-derived suppressor cell elements may enhance the antitumor activity of GM-CSF. GM-CSF has been particularly effective in studies of oncolytic HSV therapy of melanoma and in combination with ipilimumab. Further research into the basic biology of GM-CSF on effector and suppressor immune cells and expanded clinical studies of combination treatments will help define the full therapeutic potential of GM-CSF in treatment of melanoma.

Abbreviations

24CTLA-4: Cytotoxic T-lymphocyte antigen 4; CR: Complete response; DC: Dendritic cells; DFS: Disease-free survival; GM-CSF: Granulocyte–macrophage colony-stimulating factor; HR: Hazard ratio; HSV: Herpes simplex viruses; IFA: Incomplete Freund’s adjuvant; KLH: Keyhole limpet hemocyanin; MDSC: Myeloid-derived suppressor cells; OS: Overall survival; PD-1: Programmed death 1; PR: Partial response; T-VEC: Talimogene laherparepvec.

Competing interests

25HLK serves as a paid consultant and advisory board member for Amgen Inc. CLS is a scientific advisory board member for Immatics Biotechnologies and Polynoma LLC and a funded investigator for GlaxoSmithKline in the field of cancer vaccines; all funds from these activities are paid to the University of Virginia, not to Dr. Slingluff personally. Dr. Slingluff is an inventor on several patents for peptides used in cancer vaccines; the patents are held by the University of Virginia Licensing and Ventures Group. CER and TH have no conflicts to declare.

Authors’ contributions

26All authors participated in critical analysis of the literature and drafting of the manuscript. All authors read and approved the final manuscript.

References 98

1.
Siegel R Naishadham D Jemal A Cancer statistics, 2012CA Cancer J Clin2012 621029
Not in our library10.3322/caac.20138
2.
National Comprehensive Cancer NetworkNCCN Guidelines® Version 2.2013 Melanoma2012 Fort Washington, PA
Not in our library
3.
Pandolfi F Cianci R Pagliari D Casciano F Bagala C Astone A Landolfi R Barone C The immune response to tumors as a tool toward immunotherapyClin Dev Immunol2011 2011894704
Not in our library10.1155/2011/894704
4.
Eggermont AM Suciu S Santinami M Testori A Kruit WH Marsden J Punt CJ Sales F Gore M Mackie R Kusic Z Dummer R Hauschild A Musat E Spatz A Keilholz U Group EM Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialLancet2008 372117126
Not in our library10.1016/s0140-6736(08)61033-8
5.
Hodi FS O’Day SJ McDermott DF Weber RW Sosman JA Haanen JB Gonzalez R Robert C Schadendorf D Hassel JC Akerley W van den Eertwegh AJ Lutzky J Lorigan P Vaubel JM Linette GP Hogg D Ottensmeier CH Lebbe C Peschel C Quirt I Clark JI Wolchok JD Weber JS Tian J Yellin MJ Nichol GM Hoos A Urba WJ Improved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010 363711723
Not in our library10.1056/nejmoa1003466
6.
Robert C Thomas L Bondarenko I O’Day S DJ M Garbe C Lebbe C Baurain JF Testori A Grob JJ Davidson N Richards J Maio M Hauschild A Miller WH Jr Gascon P Lotem M Harmankaya K Ibrahim R Francis S Chen TT Humphrey R Hoos A Wolchok JD Ipilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011 36425172526
Not in our library10.1056/nejmoa1104621
7.
Atkins MB Lotze MT Dutcher JP Fisher RI Weiss G Margolin K Abrams J Sznol M Parkinson D Hawkins M Paradise C Kunkel L Rosenberg SA High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993J Clin Oncol1999 1721052116
Not in our library10.1200/jco.1999.17.7.2105
8.
Rosenberg SA Yang JC Sherry RM Kammula US Hughes MS Phan GQ Citrin DE Restifo NP Robbins PF Wunderlich JR Morton KE Laurencot CM Steinberg SM White DE Dudley ME Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapyClin Cancer Res2011 1745504557
Not in our library10.1158/1078-0432.ccr-11-0116
9.
Metcalf D Hematopoietic cytokinesBlood2008 111485491
Not in our library10.1182/blood-2007-03-079681
10.
Hercus TR Thomas D Guthridge MA Ekert PG King-Scott J Parker MW Lopez AF The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in diseaseBlood2009 11412891298
Not in our library10.1182/blood-2008-12-164004
11.
Dranoff G Jaffee E Lazenby A Golumbek P Levitsky H Brose K Jackson V Hamada H Pardoll D Mulligan RC Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunityProc Natl Acad Sci USA1993 9035393543
Not in our library10.1073/pnas.90.8.3539
12.
Lonial S Akhtari M Kaufman J Torre C Lechowicz MJ Flowers C Sinha R Khoury HJ Langston AA Waller EK Mobilization of hematopoietic progenitors from normal donors using the combination of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor results in fewer plasmacytoid dendritic cells in the graft and enhanced donor T cell engraftment with Th1 polarization: results from a randomized clinical trialBiol Blood Marrow Transplant2013 19460467
Not in our library10.1016/j.bbmt.2012.11.017
13.
Lonial S Hicks M Rosenthal H Langston A Redei I Torre C Duenzl M Feinstein B Cherry J Waller EK A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell productsBiol Blood Marrow Transplant2004 10848857
Not in our library10.1016/j.bbmt.2004.07.008
14.
Mach N Gillessen S Wilson SB Sheehan C Mihm M Dranoff G Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligandCancer Res2000 6032393246
Not in our library
15.
Choudhury BA Liang JC Thomas EK Flores-Romo L Xie QS Agusala K Sutaria S Sinha I Champlin RE Claxton DF Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responsesBlood1999 93780786
Not in our library
16.
Boyer MW Waller EK Bray RA Unangst T Johnson TS Phillips C Jurickova I Winton EF Yeager AM Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cellsLeukemia2000 14412418
Not in our library10.1038/sj.leu.2401685
17.
Leukine® (sargramostim)Full Prescribing Information2009 Cambridge, MA: Genzyme Corporation
Not in our library
18.
Ahlers JD Dunlop N Alling DW Nara PL Berzofsky JA Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs: granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytesJ Immunol1997 15839473958
Not in our library
19.
Reilly RT Gottlieb MB Ercolini AM Machiels JP Kane CE Okoye FI Muller WJ Dixon KH Jaffee EM HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic miceCancer Res2000 6035693576
Not in our library
20.
Reilly RT Machiels JP Emens LA Ercolini AM Okoye FI Lei RY Weintraub D Jaffee EM The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumorsCancer Res2001 61880883
Not in our library
21.
Borrello I Pardoll D GM-CSF-based cellular vaccines: a review of the clinical experienceCytokine Growth Factor Rev2002 13185193
Not in our library10.1016/s1359-6101(01)00034-x
22.
Simmons AD Li B Gonzalez-Edick M Lin C Moskalenko M Du T Creson J VanRoey MJ Jooss K GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of actionCancer Immunol Immunother2007 5616531665
Not in our library10.1007/s00262-007-0315-2
23.
Ju DW Cao X Acres B Active specific immunotherapy of pulmonary metastasis with vaccinia melanoma oncolysate prepared from granulocyte/macrophage-colony-stimulating-factor-gene-encoded vaccinia virusJ Cancer Res Clin Oncol1996 122716722
Not in our library10.1007/bf01209118
24.
Ju DW Cao X Acres B Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a mixture melanoma modelCancer Gene Ther1997 4139144
Not in our library
25.
Toda M Martuza RL Rabkin SD Tumor growth inhibition by intratumoral inoculation of defective herpes simplex virus vectors expressing granulocyte-macrophage colony-stimulating factorMol Ther2000 2324329
Not in our library10.1006/mthe.2000.0130
26.
Liu BL Robinson M Han ZQ Branston RH English C Reay P McGrath Y Thomas SK Thornton M Bullock P Love CA Coffin RS ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour propertiesGene Ther2003 10292303
Not in our library10.1038/sj.gt.3301885
27.
Li B VanRoey M Wang C Chen TH Korman A Jooss K Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor–secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumorsClin Cancer Res2009 1516231634
Not in our library10.1158/1078-0432.ccr-08-1825
28.
Quezada SA Peggs KS Curran MA Allison JP CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cellsJ Clin Invest2006 11619351945
Not in our library10.1172/jci27745
29.
Topalian SL Hodi FS Brahmer JR Gettinger SN Smith DC McDermott DF Powderly JD Carvajal RD Sosman JA Atkins MB Leming PD Spigel DR Antonia SJ Horn L Drake CG Pardoll DM Chen L Sharfman WH Anders RA Taube JM McMiller TL Xu H Korman AJ Jure-Kunkel M Agrawal S McDonald D Kollia GD Gupta A Wigginton JM Sznol M Safety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012 36624432454
Not in our library10.1056/nejmoa1200690
30.
van Elsas A Hurwitz AA Allison JP Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentationJ Exp Med1999 190355366
Not in our library10.1084/jem.190.3.355
31.
Weber J Immune checkpoint proteins: a new therapeutic paradigm for cancer–preclinical background: CTLA-4 and PD-1 blockadeSemin Oncol2010 37430439
Not in our library10.1053/j.seminoncol.2010.09.005
32.
Choi KJ Kim JH Lee YS Kim J Suh BS Kim H Cho S Sohn JH Kim GE Yun CO Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effectGene Ther2006 1310101020
Not in our library10.1038/sj.gt.3302759
33.
Li B Lin J Vanroey M Jure-Kunkel M Jooss K Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAbClin Immunol2007 1257687
Not in our library10.1016/j.clim.2007.07.005
34.
Prell RA Li B Lin JM VanRoey M Jooss K Administration of IFN-alpha enhances the efficacy of a granulocyte macrophage colony stimulating factor-secreting tumor cell vaccineCancer Res2005 6524492456
Not in our library10.1158/0008-5472.can-04-1975
35.
Stagg J Wu JH Bouganim N Galipeau J Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapyCancer Res2004 6487958799
Not in our library10.1158/0008-5472.can-04-1776
36.
Li B Lalani AS Harding TC Luan B Koprivnikar K Huan Tu G Prell R VanRoey MJ Simmons AD Jooss K Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapyClin Cancer Res2006 1268086816
Not in our library10.1158/1078-0432.ccr-06-1558
37.
Spitler LE Grossbard ML Ernstoff MS Silver G Jacobs M Hayes FA Soong SJ Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factorJ Clin Oncol2000 1816141621
Not in our library10.1200/jco.2000.18.8.1614
38.
Spitler LE Weber RW Allen RE Meyer J Cruickshank S Garbe E Lin HY Soong SJ Recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanomaJ Immunother2009 32632637
Not in our library10.1097/cji.0b013e3181a7d60d
39.
Daud AI Mirza N Lenox B Andrews S Urbas P Gao GX Lee JH Sondak VK Riker AI Deconti RC Gabrilovich D Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factorJ Clin Oncol2008 2632353241
Not in our library10.1200/jco.2007.13.9048
40.
Lawson DH Lee SJ Tarhini AA Margolin KA Ernstoff MS Kirkwood JM E4697: Phase III cooperative group study of yeast-derived granulocyte macrophage colonystimulating factor (GM-CSF) versus placebo as adjuvant treatment of patients with completely resected stage III-IV melanomaJ Clin Oncol2010 28abstr 8504
Not in our library
41.
Markovic S Burch PA LaPlant B Heun JM Bradshaw R Adjuvant GM-CSF therapy for patients with resected stage III/IV melanoma: A retrospective review of a single-center experienceJ Clin Oncol2011 29abstr 8596
Not in our library
42.
Isla D Filipovich E Mayordomo JI Andres R Puig S Escudero MP Gallego O Trujillo R Revenga F Alvarez I Saenz A Polo E Tres A Daily GM-CSF for patients with very high-risk resected melanoma: a pilot trialProc Am Soc Clin Oncol2002 21abstr 2784
Not in our library
43.
Elias EG Zapas JL McCarron EC Beam SL Hasskamp JH Culpepper WJ Sequential administration of GM-CSF (Sargramostim) and IL-2 +/−autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trialCancer Biother Radiopharm2008 23285291
Not in our library10.1089/cbr.2007.0438
44.
Si Z Hersey P Coates AS Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSFMelanoma Res1996 6247255
Not in our library10.1097/00008390-199606000-00008
45.
Nasi ML Lieberman P Busam KJ Prieto V Panageas KS Lewis JJ Houghton AN Chapman PB Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cellsCytokines Cell Mol Ther1999 5139144
Not in our library
46.
Hoeller C Jansen B Heere-Ress E Pustelnik T Mossbacher U Schlagbauer-Wadl H Wolff K Pehamberger H Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastasesJ Invest Dermatol2001 117371374
Not in our library10.1046/j.0022-202x.2001.01427.x
47.
Rao RD Anderson PM Arndt CA Wettstein PJ Markovic SN Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancerAm J Clin Oncol2003 26493498
Not in our library10.1097/01.coc.0000037664.04141.d0
48.
Markovic SN Suman VJ Nevala WK Geeraerts L Creagan ET Erickson LA Rowland KM Jr Morton RF Horvath WL Pittelkow MR A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG StudyAm J Clin Oncol2008 31573579
Not in our library10.1097/coc.0b013e318173a536
49.
Sato T Eschelman DJ Gonsalves CF Terai M Chervoneva I McCue PA Shields JA Shields CL Yamamoto A Berd D Mastrangelo MJ Sullivan KL Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factorJ Clin Oncol2008 2654365442
Not in our library10.1200/jco.2008.16.0705
50.
Eschelman DJ Gonsalves CF Terai M Laudadio M Sullivan KL Mastrangelo MJ Sato T The results of a randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in uveal melanoma patients with hepatic metastasisJ Clin Oncol2011 29abstr 8577
Not in our library
51.
Vaquerano JE Cadbury P Treseler P Sagebiel R Leong SP Regression of in-transit melanoma of the scalp with intralesional recombinant human granulocyte-macrophage colony-stimulating factorArch Dermatol1999 13512761277
Not in our library10.1001/archderm.135.10.1276
52.
Ridolfi L Ridolfi R Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanomaHepatogastroenterology2002 49335339
Not in our library
53.
Schachter J Rakowsky E Sulkes A Adler A A sequential four-drug chemotherapy and biotherapy with interferon alpha and GM-CSF–an innovative protocol for the treatment of metastatic melanomaCancer Biother Radiopharm1998 13155164
Not in our library10.1089/cbr.1998.13.155
54.
Fruehauf JP Kong KM Jakowatz JG Docetaxel and vinorelbine plus GM-CSF in malignant melanomaOncology (Williston Park)2005 191922
Not in our library
55.
Jin S Zhang Q Kang X Wang J Sun W Malignant melanoma therapy by chemotherapy and autoimmunity induced by cytokineCancer Biother Radiopharm2009 24237241
Not in our library10.1089/cbr.2008.0552
56.
O’Day SJ Atkins MB Boasberg P Wang HJ Thompson JA Anderson CM Gonzalez R Lutzky J Amatruda T Hersh EM Weber JS Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanomaJ Clin Oncol2009 2762076212
Not in our library10.1200/jco.2008.20.3075
57.
Locke F Clark JI Gajewski TF A phase II study of oxaliplatin, docetaxel, and GM-CSF in patients with previously treated advanced melanomaCancer Chemother Pharmacol2010 65509514
Not in our library10.1007/s00280-009-1057-y
58.
Lutzky J Weber R Nunez Y Gillett M Spitler L A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanomaJ Immunother2009 327985
Not in our library10.1097/cji.0b013e31818c8aaf
59.
Vaughan MM Moore J Riches PG Johnston SR A’Hern RP Hill ME Eisen T Ayliffe MJ Thomas JM Gore ME GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): a phase I trial in melanomaAnn Oncol2000 1111831189
Not in our library10.1023/a:1008348005349
60.
Gajewski T Flickinger S A phase II study of outpatient chemoimmunotherapy using cisplatin and DTIC followed by GM-CSF, IL-2, and IFN-2b in patients (pts) with metastatic melanomaProc Am Soc Clin Oncol2000 19abstr 2271
Not in our library
61.
Gibbs P O’Day S Richards J Weber J Anderson C Gonzalez R Biochemotherapy (BCT) for stage IV melanoma incorporating temozolomide, decrescendo interleukin-2 (IL-2) and GM-CSFProc Am Soc Clin Oncol2000 192255
Not in our library10.1081/cnv-58832
62.
Gong I-Y Swiger S Gajewski T Integration of GM-CSF into outpatient chemoimmunotherapy for metastatic melanomaProc Am Soc Clin Oncol2002 212790
Not in our library
63.
Groenewegen G Bloem A De Gast GC Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alphaCancer Immunol Immunother2002 51630636
Not in our library10.1007/s00262-002-0323-1
64.
de Gast GC Batchelor D Kersten MJ Vyth-Dreese FA Sein J van de Kasteele WF Nooijen WJ Nieweg OE de Waal MA Boogerd W Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanomaBr J Cancer2003 88175180
Not in our library10.1038/sj.bjc.6600717
65.
Smith IJ Kurt RA Baher AG Denman S Justice L Doran T Gilbert M Alvord WG Urba WJ Immune effects of escalating doses of granulocyte-macrophage colony-stimulating factor added to a fixed, low-dose, inpatient interleukin-2 regimen: a randomized phase I trial in patients with metastatic melanoma and renal cell carcinomaJ Immunother2003 26130138
Not in our library10.1097/00002371-200303000-00005
66.
Lewis KD Gibbs P O’Day S Richards J Weber J Anderson C Zeng C Baron A Russ P Gonzalez R A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSFCancer Invest2005 23303308
Not in our library10.1081/cnv-58832
67.
Weber RW O’Day S Rose M Deck R Ames P Good J Meyer J Allen R Trautvetter S Timmerman M Cruickshank S Cook M Gonzalez R Spitler LE Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanomaJ Clin Oncol2005 2389929000
Not in our library10.1200/jco.2005.02.5791
68.
Gunturu KS Meehan KR Mackenzie TA Crocenzi TS McDermott D Usherwood EJ Margolin KA Crosby NA Atkins MB Turk MJ Ahonen C Fuse S Clark JI Fisher JL Noelle RJ Ernstoff MS Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recoveryJ Clin Oncol2010 2811961202
Not in our library10.1200/jco.2009.24.8153
69.
Lutzky J Lawson DH Enriquez-Nunez Y Gabrilovich D Phase II trial of high-dose interleukin-2 (IL-2) with priming and concomitant sargramostim (GM-CSF) in patients with advanced melanomaJ Clin Oncol2010 28abstr 8560
Not in our library
70.
Ali OA Emerich D Dranoff G Mooney DJ In situ regulation of DC subsets and T cells mediates tumor regression in miceSci Transl Med2009 18ra19
Not in our library10.1126/scitranslmed.3000359
71.
Faries MB Hsueh EC Ye X Hoban M Morton DL Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccineClin Cancer Res2009 1570297035
Not in our library10.1158/1078-0432.ccr-09-1540
72.
Slingluff CL Jr Petroni GR Yamshchikov GV Barnd DL Eastham S Galavotti H Patterson JW Deacon DH Hibbitts S Teates D Neese PY Grosh WW Chianese-Bullock KA Woodson EM Wiernasz CJ Merrill P Gibson J Ross M Engelhard VH Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cellsJ Clin Oncol2003 2140164026
Not in our library10.1200/jco.2003.10.005
73.
Walter S Weinschenk T Stenzl A Zdrojowy R Pluzanska A Szczylik C Staehler M Brugger W Dietrich PY Mendrzyk R Hilf N Schoor O Fritsche J Mahr A Maurer D Vass V Trautwein C Lewandrowski P Flohr C Pohla H Stanczak JJ Bronte V Mandruzzato S Biedermann T Pawelec G Derhovanessian E Yamagishi H Miki T Hongo F Takaha N Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survivalNat Med2012 1812541261
Not in our library10.1038/nm.2883
74.
Chianese-Bullock KA Pressley J Garbee C Hibbitts S Murphy C Yamshchikov G Petroni GR Bissonette EA Neese PY Grosh WW Merrill P Fink R Woodson EM Wiernasz CJ Patterson JW Slingluff CL Jr MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanomaJ Immunol2005 17430803086
Not in our library10.4049/jimmunol.174.5.3080
75.
Scheibenbogen C Schadendorf D Bechrakis NE Nagorsen D Hofmann U Servetopoulou F Letsch A Philipp A Foerster MH Schmittel A Thiel E Keilholz U Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptidesInt J Cancer2003 104188194
Not in our library10.1002/ijc.10961
76.
Scheibenbogen C Schmittel A Keilholz U Allgauer T Hofmann U Max R Thiel E Schadendorf D Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanomaJ Immunother2000 23275281
Not in our library10.1097/00002371-200003000-00012
77.
Jager E Ringhoffer M Dienes HP Arand M Karbach J Jager D Ilsemann C Hagedorn M Oesch F Knuth A Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivoInt J Cancer1996 675462
Not in our library10.1002/(sici)1097-0215(19960703)67:1<54::aid-ijc11>3.0.co;2-c
78.
Kirkwood JM Lee S Moschos SJ Albertini MR Michalak JC Sander C Whiteside T Butterfield LH Weiner L Immunogenicity and antitumor effects of vaccination with peptide vaccine+/−granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696Clin Cancer Res2009 1514431451
Not in our library10.1158/1078-0432.ccr-08-1231
79.
Soiffer R Hodi FS Haluska F Jung K Gillessen S Singer S Tanabe K Duda R Mentzer S Jaklitsch M Bueno R Clift S Hardy S Neuberg D Mulligan R Webb I Mihm M Dranoff G Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanomaJ Clin Oncol2003 2133433350
Not in our library10.1200/jco.2003.07.005
80.
Soiffer R Lynch T Mihm M Jung K Rhuda C Schmollinger JC Hodi FS Liebster L Lam P Mentzer S Singer S Tanabe KK Cosimi AB Duda R Sober A Bhan A Daley J Neuberg D Parry G Rokovich J Richards L Drayer J Berns A Clift S Cohen LK Mulligan RC Dranoff G Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanomaProc Natl Acad Sci USA1998 951314113146
Not in our library10.1073/pnas.95.22.13141
81.
Slingluff CL Jr Petroni GR Olson WC Smolkin ME Ross MI Haas NB Grosh WW Boisvert ME Kirkwood JM Chianese-Bullock KA Effect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trialClin Cancer Res2009 1570367044
Not in our library10.1158/1078-0432.ccr-09-1544
82.
Schaefer C Butterfield LH Lee S Kim GG Visus C Albers A Kirkwood JM Whiteside TL Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696)Int J Cancer2012 131874884
Not in our library10.1002/ijc.26481
83.
Filipazzi P Valenti R Huber V Pilla L Canese P Iero M Castelli C Mariani L Parmiani G Rivoltini L Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccineJ Clin Oncol2007 2525462553
Not in our library10.1200/jco.2006.08.5829
84.
Parmiani G Castelli C Pilla L Santinami M Colombo MP Rivoltini L Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patientsAnn Oncol2007 18226232
Not in our library10.1093/annonc/mdl158
85.
Harrington KJ Hingorani M Tanay MA Hickey J Bhide SA Clarke PM Renouf LC Thway K Sibtain A McNeish IA Newbold KL Goldsweig H Coffin R Nutting CM Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neckClin Cancer Res2010 1640054015
Not in our library10.1158/1078-0432.ccr-10-0196
86.
Hu JCC Coffin RS Davis CJ A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factorClin Cancer Res2006 1267376747
Not in our library10.1158/1078-0432.ccr-06-0759
87.
Kaufman HL Kim DW DeRaffele G Mitcham J Coffin RS Kim-Schulze S Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanomaAnn Surg Oncol2010 17718730
Not in our library10.1245/s10434-009-0809-6
88.
Senzer NN Kaufman HL Amatruda T Nemunaitis M Reid T Daniels G Gonzalez R Glaspy J Whitman E Harrington K Goldsweig H Marshall T Love C Coffin R Nemunaitis JJ Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanomaJ Clin Oncol2009 2757635771
Not in our library10.1200/jco.2009.24.3675
89.
Andtbacka RHI Collichio FA Amatruda T Senzer NN Chesney J Delman KA Spitler LE Puzanov I Doleman S Ye Y Vanderwalde AM Coffin R Kaufman H OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanomaJ Clin Oncol2013 31abstr LBA9008
Not in our library
90.
Hodi FS Lee SJ McDermott DF Rao UNM Butterfield LH Tarhini AA Leming PD Puzanov I Kirkwood JM Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608J Clin Oncol2013 31abstr CRA9007
Not in our library
91.
Heo J Breitbach CJ Moon A Kim CW Patt R Kim MK Lee YK Oh SY Woo HY Parato K Rintoul J Falls T Hickman T Rhee BG Bell JC Kirn DH Hwang TH Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacyMol Ther2011 1911701179
Not in our library10.1038/mt.2011.39
92.
Higano CS Corman JM Smith DC Centeno AS Steidle CP Gittleman M Simons JW Sacks N Aimi J Small EJ Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancerCancer2008 113975984
Not in our library10.1002/cncr.23669
93.
Schoenfeld J Jinushi M Nakazaki Y Wiener D Park J Soiffer R Neuberg D Mihm M Hodi FS Dranoff G Active immunotherapy induces antibody responses that target tumor angiogenesisCancer Res2010 701015010160
Not in our library10.1158/0008-5472.can-10-1852
94.
Senzer N Barve M Kuhn J Melnyk A Beitsch P Lazar M Lifshitz S Magee M Oh J Mill SW Bedell C Higgs C Kumar P Yu Y Norvell F Phalon C Taquet N Rao DD Wang Z Jay CM Pappen BO Wallraven G Brunicardi FC Shanahan DM Maples PB Nemunaitis J Phase I trial of “bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell” vaccine (FANG) in advanced cancerMol Ther2012 20679686
Not in our library10.1038/mt.2011.269
95.
Adamina M Rosenthal R Weber WP Frey DM Viehl CT Bolli M Huegli RW Jacob AL Heberer M Oertli D Marti W Spagnoli GC Zajac P Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanomaMol Ther2010 18651659
Not in our library10.1038/mt.2009.275
96.
Weide B Pascolo S Scheel B Derhovanessian E Pflugfelder A Eigentler TK Pawelec G Hoerr I Rammensee HG Garbe C Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patientsJ Immunother2009 32498507
Not in our library10.1097/cji.0b013e3181a00068
97.
Dillman RO Cornforth AN Depriest C McClay EF Amatruda TT de Leon C Ellis RE Mayorga C Carbonell D Cubellis JM Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanomaJ Immunother2012 35641649
Not in our library10.1097/cji.0b013e31826f79c8
98.
Perales MA Yuan J Powel S Gallardo HF Rasalan TS Gonzalez C Manukian G Wang J Zhang Y Chapman PB Krown SE Livingston PO Ejadi S Panageas KS Engelhorn ME Terzulli SL Houghton AN Wolchok JD Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanomaMol Ther2008 1620222029
Not in our library10.1038/mt.2008.196

Cited by papers we hold 4

Targeting Myeloid Cells in Combination Treatments for Glioma and Other Tumors · 2019
Not checked
The CD14+HLA-DRlo/neg Monocyte: An Immunosuppressive Phenotype That Restrains Responses to Cancer Immunotherapy · 2019
No notice
Hypoxia Modifies the Transcriptome of Human NK Cells, Modulates Their Immunoregulatory Profile, and Influences NK Cell Subset Migration · 2018
No notice
Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach. · 2017
Not checked

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.